To study use of N- Acetylcysteine (NAC) as an adjunct therapy in the management of lower extremity vascular injuries

To evaluate the impact of N-Acetylcysteine (NAC) use in the treatment of traumatic lower extremity vascular injury â?? A Pilot Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/05/052257

Enrollment

Registered

2023-05-03

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S759- Injury of unspecified blood vesselat hip and thigh level Health Condition 2: S859- Injury of unspecified blood vesselat lower leg level

Interventions

Intervention1: N-Acetylcysteine (NAC) GROUP-A: 5 days N-acetylcysteine 20% 1200 mg in 100ml DNS iv bd over 30 â?? 60 mins Control Intervention1: Placebo: Dextrose Normal Saline 100ml iv twice daily o

Eligibility

Inclusion criteria

Inclusion criteria: Traumatic lower extremity vascular injury in whom upfront amputation is not planned

Exclusion criteria

Exclusion criteria: •Paediatric patients of age •Pregnant or lactating women •Patients with known, pre-existent asthma or allergies, malignancy, diabetes or immunocompromised patients •Patients who have not consented for the study

Design outcomes

Primary

Measure	Time frame
1.To compare the limb salvageability rate at 30 days post injury between NAC treatment group and the placebo group. Timepoint: 30 DAYS LIMB SALVAGEABILITY	—

Secondary

Measure	Time frame
Wound healing Surgical site infection rate Wound closure rateTimepoint: 30 days	—

Countries

India

Contacts

Public ContactShankarnath S

JaiPrakash Narayan Apex Trauma Centre

dr_bagaria@yahoo.co.in9914201918

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026